Opinion

Video

Key Takeaways for Concurrent Biomarker Testing in NSCLC

Author(s):

Zofia Piotrowska, MD, MHSMartin Dietrich, MD, PhD

Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, emphasize the critical role of both tissue and liquid biopsies, the necessity of rapid time-to-treatment initiation, and the increasing likelihood of liquid biopsies becoming the standard of care for metastatic non-small cell lung cancer patients in the near future.

Related Videos
Shirish M. Gadgeel, MD
Jacob Sands, MD
Charu Aggarwal, MD, MPH, FASCO
Andrea Wolf, MD, MPH
Nagashree Seetharamu, MD, MBBS
Shirish M. Gadgeel, MD
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie
T. Jeroen N. Hiltermann, MD, of University of Groningen
Benjamin Besse, MD, PhD, of Institute Gustave Roussy
Related Content
FDA
September 25th 2024

FDA Approves Osimertinib for Locally Advanced, Unresectable EGFR+ NSCLC After Chemoradiation

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Jason Zhu, MD, MBA, executive director and chief executive officer of Henlius Biotech
September 23rd 2024

First-Line Serplulimab Receives Positive CHMP Opinion for ES-SCLC

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Charnita Zeigler-Johnson, PhD, MPH
Published: September 20th 2024 | Updated: September 20th 2024

Fox Chase Cancer Center Researchers Examine Perceptions of Smoking Stigma Among African American/Black Populations

FDA
September 19th 2024

FDA Approves Amivantamab Plus Chemo for EGFR+ Advanced NSCLC After an EGFR Inhibitor